
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The National Institutes of Health's Panel on Clinical Practices for Treatment of HIV Infection has recommended that Viread and Videx EC plus a nonnucleoside reverse transciptase inhibitor not be used as in initial regimen for treatment-naive patients because studies show the regimen has a high failure rate. They panel also recommended that Kaletra be dosed once daily for treatment-naive patients. Once-daily Kaletra dosing is not recommended for treatment-experienced patients.
From our Sponsors
Most Popular
Plus: Featured Video